Human complement C-5

By Targets:	Complement System (10)
By Research Areas:	Cancer (1) Cardiovascular Disease (2) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (1)

Targets Recommended: Complement System Human leukocyte immunoglobulin (Ig)-like receptors (LILR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99786

Pozelimab REGN3918	Complement System	Metabolic Disease
Pozelimab (REGN3918) is a fully human IgG4 *anti-C5* monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .

HY-128342

Complement C5-IN-1 1 Publications Verification	Complement System	Inflammation/Immunology
Compound C5-IN-1 (Compound 7) is a selective allosteric inhibitor of complement component protein C5. Compound C5-IN-1 prevents C5 from being cleaved by C5 convertase, inhibits the cleavage of C5 into C5a and C5b, and thus blocks the formation of membrane attack complex (MAC). Compound C5-IN-1 has an IC₅₀ of 0.77 μM and 5 nM in 50% human whole blood and 2% human serum to block MAC deposition induced by zymosan, respectively. Compound C5-IN-1 can be used to study diseases related to complement overactivation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) .

HY-P9914

Eculizumab 1 Publications Verification Anti-Human C5, Humanized Antibody; h5G1.1	Complement System	Cardiovascular Disease Neurological Disease
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .

HY-P99965

Crovalimab SKY59; RO7112689; RG-6107	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the **complement C5a receptor 1 (C5aR1)** that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-138161

JR14a Maximum Cited Publications 8 Publications Verification	Complement System	Inflammation/Immunology
JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation .

HY-P2882

Human complement C5	Complement System	Inflammation/Immunology
Human complement C5 is a precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system.

HY-NP202C

C5 Protein (human)	Complement System	Inflammation/Immunology
C5 Protein (human) is a naturally occurring glycosylated polypeptide containing two disulfide-linked chains. C5 is essential for the formation of the membrane attack complex (MAC) and is activated by all three pathways of complement activation .

HY-P991067

Vensobafusp alfa KP-104	Complement System	Inflammation/Immunology
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .

Cat. No.	Product Name	Type

HY-P2882

Human complement C5	Biochemical Assay Reagents
Human complement C5 is a precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system.

HY-NP202C

C5 Protein (human)	Biochemical Assay Reagents
C5 Protein (human) is a naturally occurring glycosylated polypeptide containing two disulfide-linked chains. C5 is essential for the formation of the membrane attack complex (MAC) and is activated by all three pathways of complement activation .

Cat. No.	Product Name	Target	Research Area

HY-P5509

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

Cat. No.	Product Name	Target	Research Area

HY-P99786

Pozelimab REGN3918	Complement System	Metabolic Disease
Pozelimab (REGN3918) is a fully human IgG4 *anti-C5* monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases .

HY-P9914

Eculizumab 1 Publications Verification Anti-Human C5, Humanized Antibody; h5G1.1	Complement System	Cardiovascular Disease Neurological Disease
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in mice. Eculizumab can be used in hemolysis studies .

HY-P99965

Crovalimab SKY59; RO7112689; RG-6107	Complement System	Cardiovascular Disease Metabolic Disease
Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research .

HY-P99365

Ravulizumab ALXN1210	Complement System	Metabolic Disease
Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis .

HY-P99450

Avdoralimab IPH 5401; Anti-C5aR1 mAb	Complement System	Inflammation/Immunology Cancer
Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the **complement C5a receptor 1 (C5aR1)** that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research .

HY-P991067

Vensobafusp alfa KP-104	Complement System	Inflammation/Immunology
Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) . .

HY-P990376

Anti-Complement C5aR1 Antibody	Inhibitory Antibodies	Inflammation/Immunology
Anti-Complement C5aR1 Antibody is a human recombinant antibody expressed in CHO cells, targeting **C5AR/C5AR1 /C5R1*. Anti-Complement* C5aR1 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.4 kDa. The isotype control for Anti-Complement C5aR1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Species:	Human (11)
Tag:	His (8) Tag Free (1) Avi (1) Fc (2)
Source:	HEK293 (9) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P700862

	Complement C5 Protein, Human (HEK293, His) 1 Publications Verification complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D	Human	HEK293
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5 Protein, Human (HEK293, His) is the recombinant human-derived Complement C5 protein, expressed by HEK293 , with C-His labeled tag.

HY-P7864

	**Complement C5a Protein, Human** rHucomplement C5/C5a; complement C5; C5a anaphylatoxin; C5a	Human	E. coli
	Complement C5/C5a Protein, Human is a recombinant human complement C5a. C5a is a 74-amino acid glycoprotein generated on activation of the C system. Complement C5 is cleaved by proteolysis in the terminal phase of complement activation generating the pro-inflammatory C5a and membrane attack complex nucleator C5b. C5a is an inflammatory mediator generated by complement activation that positively regulates various arms of immune defense, including Toll-like receptor 4 (TLR4) signaling. Complement C5a Protein, Human is a human-derived recombinant protein that expressed by E. coli.

HY-P74375

	*C2/Complement* C2 Protein, Human (HEK293, His)** complement C2; C3/C5 convertase; C2	Human	HEK293
	C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, His) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-His labeled tag.

HY-P705144

	Complement C5 Protein, Human (Biotinylated, HEK293, His-Avi) C5a; complement C5; C5; CPAMD4; ECLZB	Human	HEK293

HY-P700959

	Complement C5a Protein, Human (His) C5a; complement C5; C5; CPAMD4; ECLZB	Human	E. coli
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5a Protein, Human (His) is the recombinant human-derived Complement C5/C5a protein, expressed by E. coli , with N-His labeled tag.

HY-P704336

	Complement C5 Protein, Human (HEK293, Fc) complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D	Human	HEK293
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5 Protein, Human (HEK293, Fc) is the recombinant human-derived Complement C5 protein, expressed by HEK293, with C-hFc labeled tag.

HY-P704546

	Complement C5 Protein, Human (R885H, HEK293, His) complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D	Human	HEK293
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5 Protein, Human (R885H, HEK293, His) is the recombinant human-derived Complement C5 protein, expressed by HEK293, with C-His labeled tag.

HY-P704547

	Complement C5 Protein, Human (W917S, HEK293, His) complement C5; C5; CPAMD4; ECLZB; C5a; C5b; C5D	Human	HEK293
	Complement C5 is activated by C5 convertase, inducing C5-C9 assembly to form the membrane attack complex. The transient C6 binding site on C5b is critical for the formation of the cleavage complex. Complement C5 Protein, Human (W917S, HEK293, His) is the recombinant human-derived Complement C5 protein, expressed by HEK293, with C-His labeled tag.

HY-P74376

	*C2/Complement* C2 Protein, Human (HEK293, Fc)** complement C2; C3/C5 convertase; C2	Human	HEK293
	C2/Complement C2 protein is essential in the classical pathway of the complement system. Activated by factor C1, C2 is cleaved into C2b and C2a. As a serine protease, C2a interacts with C4b, generating the C3 or C5 convertase. This crucial process activates and amplifies the complement cascade. C2/Complement C2 Protein, Human (HEK293, Fc) is the recombinant human-derived C2/Complement C2 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P700398

	C5AR1 Protein-VLP, Human (HEK293, His) complement component 5a receptor 1; C5R1, complement component 5 receptor 1 (C5a ligand); C5a anaphylatoxin chemotactic receptor; C5A; C5AR; CD88; C5a-R; C5a ligand; C5a anaphylatoxin receptor; complement component 5 receptor 1; C5R1;	Human	HEK293
	C5AR1 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays. If VLP control is required, it is recommended HY-P701236. Tags can only be detected under denaturing conditions.

HY-P7813

	Complement Factor B/CFB Protein, Human (HEK293, His) rHucomplement Factor B, His; complement Factor B; C3/C5 Convertase; Glycine-Rich Beta Glycoprotein; GBG; PBF2; Properdin Factor B; CFB; BF; BFD	Human	HEK293
	Complement Factor B/CFB Protein, Human (HEK293, His) is the recombinant human-derived Complement Factor B/CFB protein, expressed by HEK293, with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Recombinant Proteins